During the second quarter, NanoEcho has not only completed product development and passed formal verification but has also successfully certified its quality management system to ISO 13485 and conducted a health economic analysis with promising results. With product development now concluded, NanoEcho is making a clear strategic shift and is now fully focused on the clinical phase.
Don’t miss Friday’s live stream, organised by G&W Fondkommission, to gain deeper insights into the significant progress NanoEcho made during the quarter and to learn more about the clinical phase that the company is now fully concentrating on.
The financial report for the second quarter is available here (in Swedish)!
